Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Research & Development (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Research & Development over the past 3 years, most recently at $16.9 million for Q4 2025.

  • Quarterly results put Research & Development at $16.9 million for Q4 2025, up 104.18% from a year ago — trailing twelve months through Dec 2025 was $44.5 million (up 11.29% YoY), and the annual figure for FY2025 was $44.5 million, up 11.29%.
  • Research & Development for Q4 2025 was $16.9 million at Tonix Pharmaceuticals Holding, up from $9.3 million in the prior quarter.
  • Over the last five years, Research & Development for TNXP hit a ceiling of $26.5 million in Q1 2023 and a floor of $7.4 million in Q1 2025.
  • Median Research & Development over the past 3 years was $11.8 million (2024), compared with a mean of $14.3 million.
  • Biggest five-year swings in Research & Development: crashed 56.7% in 2024 and later skyrocketed 104.18% in 2025.
  • Tonix Pharmaceuticals Holding's Research & Development stood at $17.1 million in 2023, then tumbled by 51.54% to $8.3 million in 2024, then soared by 104.18% to $16.9 million in 2025.
  • The last three reported values for Research & Development were $16.9 million (Q4 2025), $9.3 million (Q3 2025), and $10.8 million (Q2 2025) per Business Quant data.